<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546428</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280X1101</org_study_id>
    <nct_id>NCT01546428</nct_id>
  </id_info>
  <brief_title>A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INC280 will be administered to Japanese patients with advanced soid tumors whose disease has&#xD;
      progressed despite standard therapy or for whom no standard therapy exists. The trial will&#xD;
      assess the safety and tolerability and determine the maximum tolerated dose (MTD) on INC280&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLT) in the dose escalation part</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence and frequency of DLT during the first cycle of INC280 treatment in the dose escalation part according to the CTCAE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events and serious adverse events, changes in laboratory values</measure>
    <time_frame>4 months</time_frame>
    <description>Incidence and severity of adverse events and serious adverse events, changes in laboratory values will be measured during the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of INC280 and derived PK parameters of INC280 such as Tmax, AUC and T1/2</measure>
    <time_frame>1 month</time_frame>
    <description>Plasma concentration of INC280 and derived PK parameters of INC280 will be measured with serial plasma samples during treatment for first months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary tumor responses according to RECIST 1.1 or MacDonald criteria for GBM</measure>
    <time_frame>4 months</time_frame>
    <description>Tumor responses will be measured according to RECIST 1.1 or MacDonald criteria for GBM</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced solid tumors that are refractory to currently available therapies or for&#xD;
             which no effective treatment is available.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status â‰¤ 2&#xD;
&#xD;
          -  Good organ (hepatic, kidney, BM) function at screening/baseline visit.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Symptomatic CNS metastases that are neurologically unstable or requiring increasing&#xD;
             doses of steroids to control CNS disease.&#xD;
&#xD;
          -  Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of INC280.&#xD;
&#xD;
          -  Undergone a bone marrow or solid organ transplant.&#xD;
&#xD;
          -  Women who are pregnant or breast feeding.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=15330</url>
    <description>Results for CINC280X1101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-MET</keyword>
  <keyword>Advanced solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

